News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Canyon Pharmaceuticals' DESIR-ABLE Study Completed


10/10/2012 8:56:06 AM

PARSIPPANY, N.J.--(BUSINESS WIRE)--DESIR-ABLE, a multicenter, open-label, single-arm study of desirudin (RevascĀ®, IprivaskĀ®) demonstrated the clinical utility and safety profile of desirudin for prevention of dangerous blood clots in a broad population of surgical and medically ill patients. Results of the study, entitled Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE), were published in Clinical and Applied Thrombosis and Hemostasis.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES